^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA mutation

    i
    Other names: BRCA, Breast cancer, early onset
    Related biomarkers:
    Expression
    CNA
    Others
    1d
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Nov 2026
    Trial completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    1d
    GENRE-2: Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study (clinicaltrials.gov)
    P=N/A, N=737, Active, not recruiting, Mayo Clinic | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2)
    |
    ATM mutation • PALB2 mutation • BRCA mutation
    2d
    COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2/3, N=582, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2026 --> Dec 2026
    Trial completion date • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    3d
    A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors (clinicaltrials.gov)
    P2, N=290, Not yet recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    New P2 trial
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab) • carboplatin
    3d
    Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2026 --> Nov 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    3d
    NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=579, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2026 --> Nov 2026
    Trial completion date • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    4d
    Clinical and Molecular Characterization of Clear Cell Adenocarcinoma of the Urinary Tract: A Multi-Institutional Study. (PubMed, Am J Surg Pathol)
    However, there was no statistical significance in the progression-free survival between cases with epithelial and mesenchymal phenotypes. CCA-UT are aggressive tumors with a heterogeneous molecular profile, underscoring the role of molecular analysis in identifying potential therapeutic options for the treatment of this pernicious tumor.
    Clinical • Journal • Tumor mutational burden • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • KMT2C (Lysine Methyltransferase 2C) • ATRX (ATRX Chromatin Remodeler) • BRCA (Breast cancer early onset) • ARID1B (AT-Rich Interaction Domain 1B)
    |
    ATM mutation • ARID1A mutation • BRCA mutation
    5d
    Reproductive Decision-Making Among BRCA1/2 Pathogenic Variants Carriers and Physicians: Attitudes Toward Preimplantation and Prenatal Genetic Testing. (PubMed, Prenat Diagn)
    The findings reveal a discrepancy between reproductive preferences of BRCA mutation carriers and current practices and knowledge among healthcare professionals. Bridging this gap will require educational efforts, development of guidelines, and a multidisciplinary approach to reproductive counseling in the context of hereditary cancer risk.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    5d
    Predicting platinum-resistance in advanced ovarian cancer: defining patient and disease characteristics to improve treatment approaches at initiation of treatment or earlier in the course of the disease. (PubMed, Front Oncol)
    In addition to platinum-based chemotherapy, 19% of patients also initiated bevacizumab as part of their front-line regimen...When exploring factors associated with response to front-line platinum-based treatment of ovarian cancer, Stage IV disease was significantly associated with resistance. As platinum resistant patients have poorer survival and fewer treatment options, it is important to further define the biology and appropriate initial management of these patients.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab)
    6d
    Design and synthesis of c-Met/PARP dual-target inhibitors for the treatment of BRCA wild-type TNBC. (PubMed, Eur J Med Chem)
    Herein, a series of novel c-Met/PARP dual-target inhibitors based on the moiety of Olaparib were designed and synthesized...In particular, L19 exhibited good in vivo antitumor activity (tumor growth inhibition (TGI) rate = 32%) in MDA-MB-231 xenograft models with low toxicity. Taken together, our designed dual c-Met/PARP inhibitors are novel and promising agents for the treatment of BRCA wild-type TNBC.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib)
    7d
    Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials. (PubMed, Cancer Treat Rev)
    Anti-PD-1/PD-L1-based ICI strategies have not led to significant improvements in outcomes for ovarian cancer. Future studies should focus on optimizing biomarker selection, evaluating combination therapies, and targeting the tumor microenvironment to enhance the efficacy of immunotherapy.
    Retrospective data • Review • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HRD • BRCA mutation
    7d
    Phase III placebo-controlled oncology trials in the last decade: evolution, methodological foundations, and clinical impact. (PubMed, Cancer Treat Rev)
    Across these contexts, placebo use has been essential for reducing bias in time-to-event endpoints, validating surrogate measures, and ensuring regulatory rigor. Collectively, evidence from the last decade indicates that placebo-controlled trials have facilitated, rather than hindered, major advances in oncology and will continue to play a critical role as treatment strategies become increasingly complex and precision driven.
    P3 data • Review • Journal • BRCA Biomarker • IO biomarker
    |
    BRCA (Breast cancer early onset)
    |
    HR positive • BRCA mutation